Dr. Martens (LON:DOCS) Insider Ije Nwokori Purchases 136 Shares

Key Points

• Ije Nwokori, an insider at Dr. Martens, purchased 136 shares of the company at an average cost of GBX 90, while also making similar purchases in August and July.
• Dr. Martens' stock is currently trading at GBX 91.55 with a market capitalization of £884.07 million and significant financial ratios highlighting its fiscal position.
• Analysts' ratings on Dr. Martens stock are mixed, with a consensus rating of "Hold" and a target price suggesting potential growth, following a recent upgrade to "buy" by Peel Hunt.

Dr. Martens plc (LON:DOCS - Get Free Report) insider Ije Nwokori purchased 136 shares of Dr. Martens stock in a transaction that occurred on Wednesday, October 8th. The stock was acquired at an average cost of GBX 90 per share, with a total value of £122.40.

Ije Nwokori also recently made the following trade(s):

• On Monday, August 11th, Ije Nwokori purchased 194 shares of Dr. Martens stock. The shares were bought at an average price of GBX 77 per share, for a total transaction of £149.38.
• On Friday, July 11th, Ije Nwokori acquired 194 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 77 per share, with a total value of £149.38.

Dr. Martens Price Performance

DOCS stock remained flat at GBX 91.55 on Thursday. The company had a trading volume of 309,094 shares, compared to its average volume of 2,176,239. The business has a 50 day simple moving average of GBX 87.86 and a two-hundred day simple moving average of GBX 72.25. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The company has a market capitalization of £884.07 million, a P/E ratio of 18,310.00, a P/E/G ratio of 6.40 and a beta of 0.11. Dr. Martens plc has a 1-year low of GBX 43.02 and a 1-year high of GBX 100.87.

Analysts Set New Price Targets

Several research firms have recently weighed in on DOCS. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Dr. Martens in a research note on Friday, July 11th. Peel Hunt raised shares of Dr. Martens to a "buy" rating in a research report on Monday, August 18th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of GBX 6,000.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.